Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...

Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE: MRK) between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class ...

After the Duchess of Sussex announced her American Riviera Orchard rebrand, she once again is facing accusations of ...

Shares of Merck & Co. Inc. MRK rallied 2.08% to $89.50 Friday, on what proved to be an all-around rough trading session for ...

SAN DIEGO, CA / ACCESS Newswire / February 20, 2025 / Robbins LLP reminds stockholders that a class action was filed on ...

Meghan Markle included a sentimental nod to her husband Prince Harry in the logo for her lifestyle brand As Ever, formerly ...

The global Microcarriers market, valued at US$2.03 billion in 2023, is forecasted to grow at a robust CAGR of 8.0%, reaching US$2.08 billion ...

Julie Levinson Werner and Sandra Halbing of Lowenstein Sandler discuss current DEI-related practices among businesses and ...

Palantir is gaining significant traction in the tech world with its AI-driven services, experiencing a dramatic stock ...

Germany’s Merck KGaA is in advanced talks to aquire the U.S. biopharmaceutical company that specializes in rare diseases and cancer.

The transaction, expected to close in the first half of this year, will cost Novartis $925 million upfront with potential ...